A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group ...

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while ...

ESLA READ THE FULL ESLA RESEARCH REPORT Business Update ARTEMIS Platform Potential in Treating Extramedullary Disease Extramedullary disease (EMD) remains one of the most significant unresolved ...

Summary: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of liquid blood cancers by engineering a patient’s own immune cells to destroy malignant targets, replicating ...

New preliminary clinical data presented at ISSCR 2026 evaluated an induced pluripotent stem cell (iPSC)-derived CAR T-cell ...

A Korean research team has developed a new viral vector technology that significantly improves the production efficiency of ...

Once best known for treating blood cancers, CAR-T therapy is now being redesigned for solid tumors, autoimmune disease, and chronic viral infections, but the review shows that safety, persistence, and ...

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like cancer, there’s a lot of pressure to optimize these therapies. This is ...

CAR T-cell therapy is expected to expand quickly across autoimmune skin diseases following an anticipated regulatory approval that might come as soon as this year.

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...